| Gene
Expressed |
Increase
in Productivity |
Status
of Project |
| Chimeric and Humanized
Antibodies
Gorman C. (1990) Mammalian cell
expression. Current Opinion.
1:36-47.
|
Redesigned the prototype
expression vector which led to up to 1,000-fold increased yield
of recombinant protein. |
Developed a transient expression
system which allowed for production of protein at a 1000
fold increase. Milligram quantities produced in a week. U.S.
Patent US05024939 issued.
|
| Anti-CD11a Humanized Monoclonal and Anti-CD18 Humanized Monoclonal |
Developed a CHO cell line expression system which allowed for the creation of production lines in 3 months. |
Genentech is co-developing the
anti-CD11a antibody with XOMA
Corporation. As of 8/01, Xanelim was in
Phase III testing.
Genentech investigated the anti-CD18 humanized antibody for the
potential treatment acute myocardial infarction. Clinical
results did not meet goals and further development was stopped.
|
| Anti-HER2 Humanized
Monoclonal Antibody |
Developed a system
to allow for rapid production of humanized antibodies. This process cut the time it took to develop a
production cell line from 9 months to 3 months. |
Genentech has commercialized
Herceptin®,
the anti-HER2 antibody,
as a treatment for breast cancer and
continues to evaluate it for other indications. |
| Anti-IgE Humanized Monoclonal Antibody |
Developed a system to allow for rapid production of variants of humanized antibodies for
in vivo efficacy testing. The small scale transient process developed allowed production of sufficient protein (milligram quantities) in a week rather than 3 months. |
Genentech is investigating
whether the anti-IgE humanized
monoclonal antibody can interfere early in the complex,
multistep process that lead to the symptoms of allergy, in
patients
who have asthma. Xolair was awaiting
FDA approval 8/01. |
Home
Services
